PDCD1 and female reproductive organ cancer: As no respective data is available for gynecologic cancer patients to date, the present study aimed to assess the association of a pretherapeutically elevated BMI on both therapy response and survival in a cohort of patients with recurrent gynecologic cancers who received the PD-1 inhibitor pembrolizumab.